Introduction
A transgenic (Tg) silkworm Bombyx mori was first produced by gene transfer utilizing a piggyBac transposon-derived vector in 2000 by Tamura et al. (1) . Since then, Tg silkworms have been developed to produce recombinant human proteins, including procollagen (2), cytokines (3, 4) , and monoclonal antibodies (MoAb) (5-7), in their cocoons and silk glands. The advantages of Tg silkworms producing recombinant human proteins are: i) somewhat larger amounts of recombinant proteins (> 1 mg per larva and/or cocoon) are expressed than those derived from other hosts, ii) physical containment of Tg silkworms is easy because the larvae move slowly and seldom escape and because the moths cannot fly, iii) human pathogens have not been found in Bombyx mori, and iv) year-round breeding is possible with an artificial diet and expanded facilities, reducing the cost of producing recombinant proteins.
Lysosomal storage diseases (LSDs) are metabolic inborn errors caused by defects in lysosomal enzymes and their related co-factors (8, 9) . LSDs are associated with excessive accumulation of intact substrates in lysosomes due to an enzyme deficiency and exhibit manifestations that are quite heterogeneous. Intravenous (iv) enzyme replacement therapy (ERT) has been developed with recombinant enzyme preparations produced by mammalian cell lines, including the Chinese hamster ovary (CHO) and human fibrosarcoma (HT1080) cell lines, that stably overexpress genes that encode human lysosomal enzymes. Since 1991, ERT has been clinically used to treat LSDs, including Gaucher's disease (10), Fabry's disease (11), Pompe's disease (12) , mucopolysaccharidoses (MPS) I (13), II (14) , VI (15) , and Wolman's disease (16) involving multi-order disorders such as hepatosplenomegaly, vascular disorders, cardiomegaly, and dysostosis multiplex. iv ERT is based on incorporation of a recombinant enzyme via cell surface glycan receptors, including the mannose receptor (MR) (10) and cationindependent mannose 6-phosphate receptor (CI-M6PR)/insulin-like growth factor type II receptor (17) , into target organs and their subsequent delivery to intracellular lysosomes to degrade accumulated substrates. However, using iv ERT with recombinant human enzyme preparations produced by mammalian cell lines to treat LSDs has several disadvantages, i.e. i) large-scale production of recombinant human lysosomal enzymes by mammalian cells is limited and costly in comparison to the large-scale production of therapeutic antibodies (5) (6) (7) and ii) the risk of pathogen infection and the risk of an immune response and adverse effects including production of neutralizing antibodies against enzyme preparations in patients with an LSD and an enzyme deficiency as a result of continuous administration (18) . Alternative human glycoprotein expression systems need to be developed as more effective, safer, and cheaper lysosomal enzyme sources to overcome these problems. Recently, the current authors succeeded in producing Tg silkworms overexpressing human lysosomal enzymes, including cathepsin A (CTSA) (19, 20) , specifically in the middle silk glands (MSGs) and purifying a catalytically active mature enzyme, allowing elucidation of their crystal structures. The purified enzyme was found to have human-like high-mannose and pauci-mannose N-glycans without insect-specific saccharides. The recombinant human glycoproteins produced by the silk glands of Tg silkworms could be clinically used to treat human diseases as glycobiologics that are slightly antigenic because of their glycan structures.
Utilizing piggyBac vectors to establish transgenic silkworms expressing human lysosomal enzymes
A Tg silkworm line expressing human CTSA in its MSGs (Tg-CTSA) was established as shown in Figure 1 . A cloned open reading frame (ORF) fragment of CTSA was inserted downstream of the upstream activation sequence (UAS) of the piggyBac vector pBac[UAS-3xP3-EGFP] plasmid (21) . The MSG-specific sericin I gene promoter (Ser1p) and its 3'-UTR region, including the BlnI site, was amplified from the genomic DNA of B. mori with PCR to construct the plasmid pBac[Ser1p-BlnI-UTR, 3xP3-DsRed2] (22) , and this plasmid was inserted into regions including the Nhe I and Bgl II sites of pBacMCS (23, 24) . To construct the plasmid pBac[Ser1p-Gal4VP16, 3xP3-DsRed2], a Gal4VP16 NheI fragment (22) was inserted into the BlnI site of the plasmid pBac[Ser1-BlnI-UTR, 3xP3-DsRed2]. To generate a transgenic line with UAS-CTSA or Ser1p-Gal4VP16, the piggyBac vector pBac[UAS-CTSA, 3xP3-egfp] or pBac[Ser1p-Gal4VP16, 3xP3-DsRed2] was co-injected with the helper plasmid pHA3PIG into pre-blastoderm embryos of the w-1 pnd strain (1). The hatched larvae were reared on an artificial mulberry diet at 25ºC. G1 embryos were screened under a fluorescence stereomicroscope equipped with an EGFP or DsRed2 filer and a UAS-CTSA or Ser1-Gal4VP16 line was obtained. The UAS-CTSA line was crossed with the Ser1p-Gal4VP16 line, and silkworms (Tg-CTSA) harboring two transgenes, UAS-CTSA and Ser1p-Gal4VP16, were produced. total recovery of cathepsin A activity was 18%, and the degree of purification was above 98% (67-fold), according to high-performance liquid chromatography (HPLC)-MS/MS under native conditions. The N-glycan structures attached to the recombinant mature CTSA purified from the MSGs are summarized in Figure 3 (center). Each mature subunit carries one N-glycan attached to the N-glycan sequon (19, 20) . According to MALDI-TOF-MS, the major N-glycan structures were Man3GlcNAc2-(M3b), GlcNAcMan3GlcNAc2-(GNb), Man2Man3GlcNAc2-( M 5 ) , G l c N A c 2 M a n 3 G l c N A c 2 -( G N 2 ) , Man3Man3GlcNAc2-(M6), Man4Man3GlcNAc2-(M7), Man3Man3GlcNAc2-(M8), and Man5Man4GlcNAc2-PA (M9). Most of the major N-glycans were highmannose forms such as M8 and pauci-mannose forms such as M3. The latter are typically found in insects and are also present in mammals as metabolic intermediates. However, fucose residues linked to the core insectspecific α-1,3-linked to GlcNAc residues were seldom detected. The N-glycosylated MoAbs purified from the cocoons of the Tg silkworm have been found to coexpress heavy and light chains containing human-like high-mannose N-glycans with no or less insect-specific core-fucose residues (7), and these N-glycosylated MoAbs have markedly higher antibody-dependent cellular cytotoxicity as antibody preparations (5,6). These Figure  2A ) (20) . As shown in Figure 2B , the cathepsin A activity of human mature CTSA at a pH 5.6 towards the artificial substrate Z-L-phenylalanyl-L-leucine was specifically observed in the MSGs but not in the posterior silk glands (PSGs) of the 5 th instar larvae of Tg-CTSA harboring two transgenes, UAS-CTSA and Ser1p-Gal4VP16, indicating that expression of CTSA is controlled by the MSG-specific Ser1 promotor. In light of the specific activity (2.7 mmol/h/mg protein) of the human cathepsin A purified from a CHO cell line stably expressing CSTA cDNA (20) , the estimated amount of CTSA expressed in the 5 th instar larvae of Tg-CTSA was about 0.1 mg/larva. Approximately one gram of enzyme preparations is reported to be necessary to continuously treat a patient with an LSD per year. An estimated 50,000 larvae are necessary to obtain and purify the same amount of functional human enzymes from the MSGs of Tg-CTSA silkworms.
Immunoblotting with each antibody against the 32-kDa and 20-kDa subunits of mature CTSA (25) revealed that three specific immunoreactive bands migrated at 52, 31, and 20 kDa, corresponding to the precursor form and mature subunits, which migrated slightly faster than those (54, 32, and 20 kDa) derived from the CHO cell line stably expressing CTSA (20) (Figure 2C) . Treatment of the recombinant CTSA proteins with peptide-N-glycosidase F (PNGaseF) revealed the presence of N-glycans attached to each precursor and mature subunit, which migrated faster at 50, 30, and 18 kDa, respectively ( Figure 2C ). These bands were equivalent in size to those of digested DNA from the CHO cell line ( Figure 2C ). These results indicate that all of the precursor (52-kDa) and mature subunits (31-kDa/20-kDa) expressed in the MSGs carry N-glycans.
Recombinant human mature CTSA (cathepsin A) was purified with three-step chromatography utilizing concanavalin A (ConA)-, butyl-, and SP-Sepharose beads. The total cathepsin A activity in the extracts derived from 1,000 larvae was 132 mmol/h. The findings suggest the recombinant human glycoproteins produced by the silk glands of Tg silkworms could be clinically used to treat human diseases as glycobiologics that are slightly antigenic because of their glycan structures.
Intracellular delivery of mature CTSA purified from silk glands to lysosomes
As described above, mature CTSA derived from the MSGs was found to carry human-like N-glycans with terminal Man and GlcNAc residues. Therefore, purified mature CTSA should be endocytosed by macrophages and monocytes by binding to the cell surface mannose receptor. However, CTSA cannot be readily incorporated via CI-M6PR and delivered to lysosomes because CTSA derived from the MSGs does not carry terminal mannose 6-phosphate residues (M6P) in its N-glycans. A study has shown that fluorescein-conjugated mature CTSA at 1 µM can be incorporated into a cultured murine monocyte cell line after incubation at 37ºC for 24 h. Intracellular granular fluorescence due to the fluorescein-CTSA was found to co-localize with that of LysoTracker, which is a late endosome/lysosomal marker (Figure 4 ). These findings indicate that CTSA can be incorporated via the mannose receptor and that the fluorescein-CTSA derived from the MSGs of Tg-CTSA can be delivered to lysosomes.
Therapeutic effects of modified CTSA derived from Tg-CTSA on fibroblasts from a patient with galactosialidosis
Over the past few years, cell-penetrating peptides (CPPs) such as oligoarginine vectors have been a powerful tool for intracellular delivery of cargo molecules, including recombinant proteins and nucleic acids (26, 27) . Mature CTSA derived from the MSGs of Tg-CTSA does not carry the terminal M6P residues in its N-glycans, so intracellular uptake of CTSA derived from Tg-CTSA via CI-M6PR is not expected. CTSA, NEU1, and GLB activity are deficient in skin fibroblasts derived from a patient with galactosialidosis (GS). Previous studies demonstrated that the recombinant human CTSA produced by CHO cell lines expressing CSTA cDNA is taken up via cell surface CI-M6PR for delivery and that this recombinant human CTSA partially restores deficient enzyme activity. Oligoarginine (R8)-conjugated CTSA (R8-CTSA) was prepared by mixing BS 3 -modified R8 peptides (26) with mature CTSA purified from MSGs at 37ºC, and the replacement (therapeutic) effects on a fibroblast cell line from a patient with GS were examined. R8-CTSA but not CTSA itself was found to restore deficient enzyme activity, including deficiencies in CTSA, NEU1, and GLB1, in a dose-and time-dependent manner. Cathepsin A activity recovered to a level equal to that of fibroblasts from a normal subject 24 h after treatment with R8-CTSA (2 µmol/h). The protection of NEU1 and GLB was also found to be partly restored. The current authors previously reported that sialylglycoconjugates, including sialyloligosaccharides, accumulate in fibroblasts from patients with GS (28) . The addition of R8-CTSA to culture medium caused a marked reduction in the sialylglycoconjugates that accumulated in fibroblasts from a patient with GS according to Maackia amurensis (MAM) lectin staining, which recognizes and binds to terminal sialic acid residues of sialylglycoconjugates (28) . Thus, R8-CTSA can be incorporated into fibroblasts via macropinocytosis with an R8 tag as a CPP, it can be delivered to lysosomes, and it can activate NEU1 to degrade accumulated sialyloligosaccharides, suggesting that R8-CTSA would therapeutically benefit patients with GS. 
Perspectives for the future
Transgenic silkworms producing recombinant human proteins and enzymes in their silk glands are a promising bioresource to provide and promote the development of slightly antigenic therapeutic glycoproteins as safe bio-medicines for the treatment of human diseases, including LSDs. Recently, the current authors established another transgenic silkworm line overexpressing a functional human lysosomal enzyme. That enzyme was produced in the MSGs at an amount of 1 mg of glycoprotein per larva and/or cocoon, but the N-glycosylated enzyme does not carry terminal M6P residues. Genetic engineering will need to add terminal M6P residues to the N-glycans attached to human lysosomal enzymes; glycosyltransferase and/or glycosidase genes could be co-expressed in the MSGs of transgenic silkworm lines. Alternatively, combining recent developments in transglycosylation technology with microbial endoglycosidases is a possibility (29) . A glycotechnology approach to the chemo-enzymatic synthesis of artificial glycopeptides/glycoproteins (neoglycoproteins) has been developed using N-glycan oxazoline derivatives and the transglycosylation activity of microbial endoglycosidases and their mutants, including endo β-N-acetylglucosaminidases such as Endo-M from Mucor hiemalis (30) , Endo-A from Arthrobacter protophormiae (31) , and Endo-D from Streptococcus pneumoniae (32) . If highmannose N-glycans carrying terminal M6P residues can be obtained as the N-glycan donor in large quantities, neoglycoenzymes could be produced for ERT to treat patients with an LSD. This could be accomplished through transglycosylation by utilizing the N-glycosylated human lysosomal enzymes derived from the silk glands of transgenic silkworms as acceptors for M6P-carrying N-glycans.
